Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
LEXINGTON, Mass., March 16, 2017 -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that James Dentzer, Chief Financial Officer and Chief Administrative Officer, will present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference on March 21, 2017 at 2:10 p.m. Eastern Time in New York.
A corresponding webcast of the presentation can be accessed, both live and archived, by visiting:
https://www.veracast.com/webcasts/opco/healthcare2017/03110203347.cfm
The webcast will be archived shortly after the live event and will be available for 90 days through June 19, 2017. It will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
